Was awarded $ 285.

Said Drcine. -d Fund invests in Breast Cancer Detection Startup companiesOne of the newest Indiana University life science ventures, CS – Keys, was awarded $ 285,000 from the Indiana Seed Fund.The company’s focus is on the early detection of breast cancer through a new diagnostic tool in the laboratory of Linda Malka, who developed Vera Bradley Professor of Oncology and professor of medicine at the Indiana University School of Medicine.

It is expected that in the future, with a simple blood test, doctors can tell their patients if they have breast cancer at its earliest stages not need Pathology Laboratories invest in additional equipment;. You only need a minimum amount of training and one spot that we developed for this purpose. CS .

Barbarroja et al. Stated that the ‘healthy’obese lacked an inflammatory response, which was found in the unhealthy, insulin resistance, obesity.

CS – Keys was formed in February 2005 with two other IU faculty associate, Robert J. Professor of Medicine and Derek J. Assistant Professor in the Department of Medicine, the new company will scientific the Indiana Seed Fund investments in several important. Complete and economic milestones, including the validation and clinical studies and completion of a market and product strategy study the company is located at the Indiana University Emerging Technologies Center in Indianapolis..The main risk for severe rash and hepatic events occurs for the first six weeks of therapy. It is important that patients will be on these reactions all times, and under intensive monitoring during the first months of treatment. VIRAMUNE should be discontinued and not be restarted next severe liver, skin or hypersensitivity reactions.. By application of the VIRAMUNE CD4 Policy risk by the liver significantly reduced. Significantly reduced. VIRAMUNE was no initiated for adult men to CD4+ cell count greater than 250 cells/mm3 respectively or in adult men with CD4+ cell counts of over 400 cells/mm3 respectively In If the benefit outweighs the risk.

Boehringer IngelheimBoehringer Ingelheim is committed to research and development of new of antiretroviral agents. Aside from VIRAMUNE .